<DOC>
	<DOCNO>NCT00139828</DOCNO>
	<brief_summary>In postmarketing study , safety Nonafact速 ( human coagulation factor IX ) evaluate previous treat untreated patient severe , moderate mild haemophilia B .</brief_summary>
	<brief_title>Post Marketing Study Haemophilia B Patients Using Nonafact速 ( Human Coagulation Factor IX )</brief_title>
	<detailed_description>The clinical efficacy safety Nonafact速 show two pre-authorisation study . Marketing authorisation EU grant 3 July 2001 . The Post Marketing Study , evaluate clinical efficacy , immunogenicity safety Nonafact速 , set accord CPMP/BPWG /198/95 , rev . 1 ( Final , London , 19 October 2000 ) 'Note guidance clinical investigation human plasma derive factor VIII IX product '</detailed_description>
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Hemophilia B</mesh_term>
	<criteria>Haemophilia B ( mild , moderate severe ) , Haemophilia B Leyden symptomatic carrier Haemophilia B Haemophilia B Leyden Above age six , moment inclusion Tested positive HAV HBV antibody , induced infection vaccination , negative HBsAg Informed consent sign patient legally accept representative Under age six , moment inclusion Tested negative HAV HBV antibody</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2007</verification_date>
	<keyword>haemophilia B</keyword>
	<keyword>factor IX</keyword>
	<keyword>Product Surveillance , Postmarketing</keyword>
	<keyword>plasma product</keyword>
</DOC>